Diabetes mellitus is a complex and multifactorial disease with a global prevalence that exceeds 425 million people. Type 2 diabetes mellitus (T2DM) is characterized by a state of insulin resistance, which leads to metabolic alterations that aggravate the state of health of people. Vitamin D deficiency appears to play an important role in the triggering mechanisms of insulin resistance. In this review, an analysis is made of the biochemical mechanisms associated with the insulin-mimetic effect of vitamin D, its supplementation being a possible nutritional strategy for the T2DM treatment. The current scientific evidence is extensive regarding the dose of vitamin D used for an insulin-mimetic effect. However, clinical trials and systematic reviews show statistical differences on glucose, insulin, and glycated hemoglobin levels of patients with T2DM, associated with activation mechanisms of transcription factors related to genes of the glucide metabolism and the insulin receptor, and the regulation of intracellular Ca2+ insulin concentrations. Likewise, an indirect mechanism associated with antioxidant and anti-inflammatory effects has been shown that also leads to sensitivity to the insulin receptor. The use of a specific dose of vitamin D could be an effective alternative in the T2DM treatment, which would reduce the risk of complications derived from hyperglycemia.
Currently, 1 in 3 people have an adiposity-based chronic disease (ABCD), a situation that in recent decades has been on the rise. The systemic oxidative stress characteristic of ABCD is a complex and systemic state that derives from the deregulation of the musculoskeletal system and the loss of cellular antioxidant capacity. In the present review, we analyze the mechanisms of antioxidant bioactive compounds that, in clinical evidence, have shown a potential effect on the reduction of oxidative stress in people with ABCD. Research presented in this review was identified through searches of PubMed/Medline, EMBASE and the Cochrane Library databases. Observational studies report that people with ABCD have lower serum concentrations of antioxidants such as vitamins C, E and coenzyme Q10. Scientific evidence affirms that the use of antioxidants in the nutritional therapy of people with ABCD results in a decrease in prooxidative markers. In clinical practice, various factors such as diet, pharmacotherapy, stress levels and disease progression could reduce the efficacy of antioxidant compounds in the nutritional treatment of ABCD. The appropriate dosage of bioactive compounds with antioxidant effects results in a potential ally in the metabolic control of people with ABCD.